A last-minute legislative reprieve keeps most hemp-derived products on American shelves — but the industry's long-term future remains unresolved.

A sweeping cost-control law strips flower from statutory insurance overnight, with no replacement pathway in place — and a constitutional fight underway.

As the UK debates regulated adult-use cannabis, Europe's largest illicit market presents a cautionary tale — and a policy opportunity.

A complex debt-for-equity deal transfers commercialisation rights to a financially fragile drinks company — with implications for patients across the EU.

As the UK's medical cannabis sector faces mounting scrutiny over weak clinical evidence, the lesson for Malta's emerging framework is clear: data collection must begin now.